Topical Cenegermin-Bkbj Dramatically Resolves Neurotrophic Keratitis Associated With Pars Plana Vitrectomy

Neurotrophic keratitis (NK) may occur secondary to pars plana vitrectomy (PPV). A subset of patients with very severe NK corneal defects may require therapy escalation, and Cenegermin-Bkbj, a recombinant human nerve growth factor, represents a novel treatment option. This case report presents the successful treatment of refractory NK using Cenegermin-Bkbj in a patient after undergoing multiple PPV surgeries. A 60-year-old woman with recurrent retinal detachments in the right eye after receiving the third PPV developed persistent irritation, photophobia, and worsening visual acuity due to iatrogenic NK despite lubrication, bandage contact lens, preservative-free artificial tears, restasis, and right lower lid punctal cautery over 6 weeks. She received daily topical Cenegermin-Bkbj for 8 weeks to achieve complete corneal reepithelialization, restoration of corneal sensation, and visual acuity improvement from hand motion to 20/80. She remained symptom-free at the 8-week follow-up. This case highlights the importance of early recognition, tailored management, and the potential efficacy of Cenegermin-Bkbj in treating NK arising after retinal procedures. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2025;56:309-311.]</b>.